Tenax Therapeutics Inc (TENX) - Total Assets
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) holds total assets worth $102.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Tenax Therapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
Tenax Therapeutics Inc - Total Assets Trend (1995–2024)
This chart illustrates how Tenax Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Tenax Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tenax Therapeutics Inc's total assets of $102.81 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Tenax Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Tenax Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tenax Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 26.9% in 1995.
- Cash Position: Cash and equivalents constituted 98.1% of total assets in 2024, up from 19.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 1995.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tenax Therapeutics Inc Competitors by Total Assets
Key competitors of Tenax Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Tenax Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.58 | 38.95 | 3.21 |
| Quick Ratio | 15.58 | 38.95 | 3.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $96.21 Million | $97.22 Million | $4.68 Million |
Tenax Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tenax Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.82 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | 727.5% |
| Total Assets | $96.69 Million |
| Market Capitalization | $78.98 Million USD |
Valuation Analysis
Near Book Valuation: The market values Tenax Therapeutics Inc's assets close to their book value (0.82x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Tenax Therapeutics Inc's assets grew by 727.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tenax Therapeutics Inc (1995–2024)
The table below shows the annual total assets of Tenax Therapeutics Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $96.69 Million | +727.46% |
| 2023-12-31 | $11.68 Million | +243.19% |
| 2022-12-31 | $3.40 Million | -43.18% |
| 2021-12-31 | $5.99 Million | -12.76% |
| 2020-12-31 | $6.87 Million | +7.91% |
| 2019-12-31 | $6.37 Million | -52.27% |
| 2018-12-31 | $13.34 Million | +34.85% |
| 2017-12-31 | $9.89 Million | -57.62% |
| 2016-12-31 | $23.34 Million | -68.02% |
| 2015-12-31 | $72.99 Million | -21.88% |
| 2014-12-31 | $93.43 Million | 0.00% |
| 2013-12-31 | $93.43 Million | +175.31% |
| 2012-12-31 | $33.94 Million | +476.14% |
| 2011-12-31 | $5.89 Million | +66.90% |
| 2010-12-31 | $3.53 Million | -29.82% |
| 2009-12-31 | $5.03 Million | -40.10% |
| 2008-12-31 | $8.39 Million | +319.42% |
| 2007-12-31 | $2.00 Million | +227.70% |
| 2006-12-31 | $610.79K | -51.61% |
| 2005-12-31 | $1.26 Million | -30.24% |
| 2004-12-31 | $1.81 Million | +21.77% |
| 2003-12-31 | $1.49 Million | +12.80% |
| 2002-12-31 | $1.32 Million | -65.26% |
| 2001-12-31 | $3.79 Million | -38.83% |
| 2000-12-31 | $6.20 Million | +1139.93% |
| 1999-12-31 | $500.00K | -49.29% |
| 1998-12-31 | $985.91K | +209.88% |
| 1997-12-31 | $318.16K | -19.24% |
| 1996-12-31 | $393.94K | 0.00% |
| 1995-12-31 | $393.94K | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatini… Read more